Statement of Changes in Beneficial Ownership (4)
July 10 2020 - 6:55PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Rice William G. |
2. Issuer Name and Ticker or Trading Symbol
Aptose Biosciences Inc.
[
APTO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chair, President & CEO |
(Last)
(First)
(Middle)
C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/10/2020 |
(Street)
TORONTO, A6 M2J 4R3
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Shares | 7/10/2020 | | S(1) | | 168891 (2) | D | $6.05 | 297523 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The reporting person's sale of APTO common stock reported herein (see footnote 2 below) was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 3,400 shares, with the reporting person's purchase of 3,400 shares of APTO common stock at a price of $5.8244 per share on March 25, 2020. The reporting person has agreed to pay to Aptose Biosciences Inc., upon settlement of the sale, $767.04, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs. |
(2) | Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 300,000 restricted stock units, previously reported on a Form 4/A filed with the Securities and Exchange Commission on March 10, 2020. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Rice William G. C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3 | X |
| Chair, President & CEO |
|
Signatures
|
/s/ Janet Clennett as attorney-in-fact for William G. Rice | | 7/10/2020 |
**Signature of Reporting Person | Date |
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Jul 2023 to Jul 2024